Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in New York City. The summit provided the opportunity to engage in face-to-face discussions with leading stakeholders on the best practices to enhance global protections for patent portfolios. Now more than ever in these increasingly challenging and globalised times, effectively and strategically prosecuting patents is critical to business success.
“This conference is very relevant to the Life Sciences IP field, offering valuable and practical insights on global IP matters. The panels consist of esteemed individuals, including IP firm partners, Heads of IP, and notable government representatives such as the Deputy Chief Judge in the Patent Trial and Appeal Board of the US Patent and Trademark Office and a Judge of the Court of Appeal at the Unified Patent Court. The conference is renowned for its high-quality discussions and expertise in the field,” said Ms Mantas.
During this year’s conference, various critical IP matters were addressed, including discussions on the new Unified Patent Court (UPC) system, meeting the requirements of enablement and written description and practical insights on how to maximise patent terms.
Additionally, there were insightful discussions on the controversies surrounding CRISPR and CAR-T intellectual property. Securing IP rights for these technologies and effectively leveraging or licensing them has become essential for the successful future development, growth and commercial prospects for numerous companies.